Used in targeted cancer therapy, particularly for colorectal and gastrointestinal cancers. Binds specifically to the GUCY2C receptor, which is overexpressed in certain tumor cells, enabling precise delivery of therapeutic agents or facilitating immune-mediated destruction of cancer cells. Investigated for use in antibody-drug conjugates (ADCs) to enhance treatment efficacy while minimizing damage to healthy tissues. Also serves as a reference standard in research and development of anti-GUCY2C immunotherapies.